Jieun Uhm

1.2k total citations
57 papers, 876 citations indexed

About

Jieun Uhm is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Jieun Uhm has authored 57 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 19 papers in Genetics and 14 papers in Oncology. Recurrent topics in Jieun Uhm's work include Hematopoietic Stem Cell Transplantation (19 papers), Acute Myeloid Leukemia Research (19 papers) and Acute Lymphoblastic Leukemia research (12 papers). Jieun Uhm is often cited by papers focused on Hematopoietic Stem Cell Transplantation (19 papers), Acute Myeloid Leukemia Research (19 papers) and Acute Lymphoblastic Leukemia research (12 papers). Jieun Uhm collaborates with scholars based in Canada, South Korea and United States. Jieun Uhm's co-authors include John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Vikas Gupta, Matthew D. Seftel, Fotios V. Michelis, Nada Hamad, Ho Yeong Lim, Eshetu G. Atenafu and Dennis Dong Hwan Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.

In The Last Decade

Jieun Uhm

53 papers receiving 865 citations

Peers

Countries citing papers authored by Jieun Uhm

Since Specialization

Citations

This map shows the geographic impact of Jieun Uhm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jieun Uhm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jieun Uhm more than expected).

Fields of papers citing papers by Jieun Uhm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jieun Uhm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jieun Uhm. The network helps show where Jieun Uhm may publish in the future.

Co-authorship network of co-authors of Jieun Uhm

This figure shows the co-authorship network connecting the top 25 collaborators of Jieun Uhm. A scholar is included among the top collaborators of Jieun Uhm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jieun Uhm. Jieun Uhm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	On the Learnability, Robustness, and Adaptability of Deep Learning Models for Obfuscation-applied Code 2025 ·Jieun Uhm, (unknown), Hyungjoon Koo	0
2	Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation 2023 ·Blood Research ·Jieun Uhm	0
3	Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey 2021 ·Blood Research ·Jieun Uhm, Kyoung Ha Kim, Hyewon Lee, Hawk Kim, (unknown), (unknown), Chul Won Jung	2
4	Recent advances in chronic lymphocytic leukemia therapy 2020 ·Blood Research ·Jieun Uhm	3
5	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD 2017 ·Annals of Hematology ·Joon Ho Moon, Nada Hamad, Sang Kyun Sohn, Jieun Uhm, (unknown), Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner, Matthew D. Seftel, John Kuruvilla, Dennis Dong Hwan Kim	10
6	Antitumoral effect of arsenic compound, sodium metaarsenite (KML001), on multiple myeloma cells 2017 ·International Journal of Oncology ·(unknown), (unknown), Sujong Kim, Jieun Uhm, Young‐Woong Won, (unknown), Jung Hye Choi, Young Yiul Lee	4
7	Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation 2016 ·Bone Marrow Transplantation ·Samantha Mayo, Hans A. Messner, Sean B. Rourke, Doris Howell, J. Charles Victor, John Kuruvilla, Jeffrey H. Lipton, Vikas Gupta, (unknown), (unknown), (unknown), (unknown), David Loach, Fotios V. Michelis, (unknown), Jieun Uhm, (unknown), Kelly Metcalfe	25
8	The potential of deferasirox as a novel therapeutic modality in gastric cancer 2016 ·World Journal of Surgical Oncology ·Jung Hye Choi, (unknown), Young‐Woong Won, Jieun Uhm, (unknown), Young Yiul Lee	23
9	Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation 2015 ·Bone Marrow Transplantation ·(unknown), Eshetu G. Atenafu, John Kuruvilla, Jieun Uhm, Jeffrey H. Lipton, Hans A. Messner, (unknown), Matthew D. Seftel, Vikas Gupta	15
10	Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2 2015 ·Bone Marrow Transplantation ·Fotios V. Michelis, Hans A. Messner, Eshetu G. Atenafu, (unknown), (unknown), Jieun Uhm, (unknown), Matthew D. Seftel, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, (unknown)	28
11	Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD 2015 ·Bone Marrow Transplantation ·(unknown), Wei Xu, Eshetu G. Atenafu, Jieun Uhm, Matthew D. Seftel, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, (unknown)	12
12	Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning 2014 ·Biology of Blood and Marrow Transplantation ·Nada Hamad, (unknown), Hans A. Messner, Dennis Kim, John Kuruvilla, Jeffrey H. Lipton, Jieun Uhm, Matthew D. Seftel, (unknown), Wei Xu, Vikas Gupta	9
13	Validation of National Institutes of Health Global Scoring System for Chronic Graft-Versus-Host Disease (GVHD) According to Overall and GVHD-Specific Survival 2014 ·Biology of Blood and Marrow Transplantation ·Joon Ho Moon, Sang Kyun Sohn, (unknown), Laura Ellis, Nada Hamad, Jieun Uhm, Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner, John Kuruvilla, Dennis Kim	33
14	Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score 2014 ·Clinical Lymphoma Myeloma & Leukemia ·Fotios V. Michelis, Hans A. Messner, Jieun Uhm, (unknown), (unknown), (unknown), Matthew D. Seftel, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, (unknown)	11
15	The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD 2014 ·Bone Marrow Transplantation ·Jieun Uhm, Nada Hamad, Fotios V. Michelis, (unknown), John Kuruvilla, Vikas Gupta, Jeffrey H. Lipton, Hans A. Messner, Matthew D. Seftel, (unknown)	48
16	Allogeneic stem cell transplantation for diffuse large B cell lymphoma: Defining the role of allografts 2013 ·Transfusion and Apheresis Science ·Jieun Uhm, John Kuruvilla	1
17	Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of Transplant 2013 ·Biology of Blood and Marrow Transplantation ·Fotios V. Michelis, Hans A. Messner, Eshetu G. Atenafu, Dennis Dong Hwan Kim, John Kuruvilla, Jeffrey H. Lipton, Jieun Uhm, David Loach, Vikas Gupta	13
18	A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation 2013 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Hans A. Messner, Suzanne Kamel‐Reid, Eshetu G. Atenafu, Vikas Gupta, John Kuruvilla, Dennis Dong Hwan Kim, Jieun Uhm, (unknown), Laura Ellis, Jeffrey H. Lipton	10
19	Multiple Single-Nucleotide Polymorphism–Based Risk Model for Clinical Outcomes After Allogeneic Stem-Cell Transplantation, Especially for Acute Graft-Versus-Host Disease 2012 ·Transplantation ·(unknown), Jina Yun, Hong‐Hee Won, Lu Cheng, Jie Su, Wei Xu, Jieun Uhm, Vikas Gupta, John Kuruvilla, Hans A. Messner, Jeffrey H. Lipton	16
20	A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer 2008 ·Cancer Chemotherapy and Pharmacology ·Kyoung Ha Kim, Young Suk Park, Myung Hee Chang, Hyo Song Kim, Hyun Jung Jun, Jieun Uhm, Seong Yoon Yi, Do Hyoung Lim, Sang Hoon Ji, Min Jae Park, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact